Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025272 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT00025272 is a Phase 2 study of Lung Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00025272, a Phase 2 study of Lung Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, and etoposide in treating patients who have extensive-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG etoposide
- RADIATION radiation therapy
- DRUG topotecan hydrochloride
Study Locations (5)
North Carolina
- Southeastern Medical Oncology Center - Goldsboro
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
South Carolina
- CCOP - Greenville - Greenville
- CCOP - Upstate Carolina - Spartanburg
Virginia
- MBCCOP - Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2001-11-01 |
| Est. Completion | 2005-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025272
The ClinicalTrials.gov registry entry for NCT00025272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00025272 reports 5 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT00025272 about?
NCT00025272 is a clinical study titled "Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, a...
What is the current status of trial NCT00025272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2001-11-01. Estimated completion is 2005-01-18.
What conditions does trial NCT00025272 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00025272?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00025272?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025272 being conducted?
This trial has 5 study locations across North Carolina, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.